Clevudine triphosphate – CAS 174625-00-4


Clevudine triphosphate is synthesised by Santiago Lab (Prague, Czech Republic).

We are providing Clevudine triphosphate in the form of Et3NH+ salt. All products are lyophilized and can easily sustain the shipment oversee.

Purity (LC-MS)

99%+ | Certificate of Analysis

Package contents

Clevudine triphosphate Et3NH+ salt

This compound is for research use only. We do not sell to patients.

We are sending Clevudine triphosphate in the form of Et3NH+ salt.

1 mg

In stock

5 mg

In stock

10 mg

In stock


In stock


In stock



CAS: 174625-00-4, 2736455-58-4 (Et3NH+ salt)

IUPAC Name: 1-​[2-​deoxy-​2-​fluoro-​5-​O-​[hydroxy[[hydroxy(ph​osphonooxy)​phosphinyl]​oxy]​phosphinyl]​-​β-​L-​arabinofuranosyl]​-​5-​methyl-2,​4(1H,​3H)​-​pyrimidinedione

Other names: Clevudine triphosphate, Clevudine TP

Molecular weight: 500.16 g/mol, 

Molecular formula: C10 H16 F N2 O14 P3

Storage: -20 °C, protect from light, stored under argon

We are providing Clevudine triphosphate in the form of Et3NH+ salt.


Clevudine triphosphate is synthesised by Santiago Lab (Prague, Czech Republic).

Clevudine (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.

Researchers in South Korea are testing clevudine at lower doses in combination with adefovir for continued use.

Chemicals are distributed worldwide

Buy Clevudine triphosphate now, get your order in 48 hours
  • Shipping through DHL in 48 hours. We can also arrange shipping on dry ice.
  • Shipping worldwide for €100. For orders over €1 500 shipping is free.
  • All compounds are safely and rigorously packed
  • We are sending the invoice the same day as the shipment
  • We can modify the invoice for the academic institution so that the order can be paid from grants

1.ak WY, Yang JM, Kim BI, Baik SK, Cheon GJ, Byun KS, Kim DY, Yoo BC, et al. (May 2014). "A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients". Hepatology International. 8 (3): 375–381. doi:10.1007/s12072-014-9537-5. PMC 4116600
2. Lee HS, Chung YH, Lee K, et al. (May 2006). "A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B". Hepatology. 43 (5): 982–8. doi:10.1002/hep.21166

Related products: